<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
   xmlns:content="http://purl.org/rss/1.0/modules/content/"
   xmlns:dc="http://purl.org/dc/elements/1.1/"
   xmlns:atom="http://www.w3.org/2005/Atom"
   xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
   xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
   xmlns:company="http://purl.org/rss/1.0/modules/company"
>
	<channel>
		<title>Latest News - Market Wire News</title>
		<atom:link href="https://marketwirenews.com/rss/news-releases/?s=cvm" rel="self" type="application/rss+xml" />
		<link>https://marketwirenews.com</link>
		<description>Market Wire News RSS News Feed for Cel-Sci Corporation (NYSE: CVM)</description>
		<lastBuildDate>Wed, 07 Oct 2026 12:13:52 -0400</lastBuildDate>
		<language>en-US</language>
		<sy:updatePeriod> hourly </sy:updatePeriod>
		<sy:updateFrequency> 60 </sy:updateFrequency>

		<image>
			<url>https://marketwirenews.com/assets/img/icons/favicon-32x32.png</url>
			<title>Market Wire News</title>
			<link>https://marketwirenews.com</link>
			<width>32</width>
			<height>32</height>
		</image>
		<item>
            <title>Market Wire News Hottest Alerts Newsletter</title>
            <link>https://marketwirenews.com/newsletter/</link>
            <pubDate>Wed, 07 Oct 2026 12:13:52 -0400</pubDate>
            <dc:creator><![CDATA[Market Wire News]]></dc:creator>
            <category><![CDATA[Stock Picks]]></category>
            <category><![CDATA[Stock ALerts]]></category>
            <description><![CDATA[Subscribe to Market Wire News newsletter for instant real-time stock alerts, breaking financial news, trending stocks, and portfolio updates delivered to your email & mobile.]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/newsletter/?v=3426</guid>
          </item>
          <item>
            <title>Market Wire News Trending Stocks</title>
            <link>https://marketwirenews.com/trending-stocks/</link>
            <pubDate>Wed, 07 Oct 2026 12:13:52 -0400</pubDate>
            <dc:creator><![CDATA[Market Wire News]]></dc:creator>
            <category><![CDATA[Stock Picks]]></category>
            <category><![CDATA[Stock ALerts]]></category>
            <description><![CDATA[Track today's hottest trending stocks on NASDAQ, NYSE, OTCMKTS & Canadian markets. See massive % gainers, real-time movers, volumes, and linked breaking news updates.]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/trending-stocks/?v=3426</guid>
          </item>
          <item>
            <title>Market Wire News Investor Awarenewss</title>
            <link>https://marketwirenews.com/advertise/</link>
            <pubDate>Wed, 07 Oct 2026 12:13:52 -0400</pubDate>
            <dc:creator><![CDATA[Market Wire News]]></dc:creator>
            <category><![CDATA[Invesor Awareness]]></category>
            <category><![CDATA[Investor Releatios]]></category>
            <description><![CDATA[Stock Promoter, Investor Relations, Investor Awareness, Market Wire News, investor brand advertisement services, plans and pricing.]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/advertise/?v=3426</guid>
          </item>
		<item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews August 17, 2026 08:30:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-reports-fiscal-third-quarter-2026-results-5803345550585143.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 17 Aug 2026 08:30:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[Peer-reviewed study in Oral Oncology identified prognostic biomarkers for selecting patients most likely to achieve substantial survival benefit from Multikine in upcoming Confirmatory Head &amp; Neck Cancer Registration Study         Dual track commercialization strategy includes the global Conf...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-reports-fiscal-third-quarter-2026-results-5803345550585143.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews August 04, 2026 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-study-published-in-peer-reviewed-oral-oncolo-8148211009077466.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 04 Aug 2026 08:00:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[The published article identified low and zero (0%) PD-L1 expression and no lymph node involvement as biomarkers for selecting patients most likely to benefit from Multikine pre-surgery treatment         Study concludes Multikine represents the first neoadjuvant treatment in decades to demonstrate...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-study-published-in-peer-reviewed-oral-oncolo-8148211009077466.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews June 24, 2026 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-and-saudi-amarox-hold-strategic-agreement-si-7506663573019492.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 24 Jun 2026 08:00:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[Ceremony highlights shared commitment to oncology innovation, healthcare advancement, and international collaboration         Strategic partnership spans regulatory, marketing, distribution, and revenue sharing agreement for Multikine&#xAE; in the treatment of head and neck cancer in Saudi Arabia...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-and-saudi-amarox-hold-strategic-agreement-si-7506663573019492.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews June 16, 2026 04:01:00 pm</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-announces-closing-of-offering-6474378985504591.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 16 Jun 2026 16:01:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[CEL-SCI Corporation (&#x201C;CEL-SCI&#x201D; or the &#x201C;Company&#x201D;) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts offering of 2,500,000 shares of its common stock. Each share of common stock was sold at an offering pr...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-announces-closing-of-offering-6474378985504591.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews June 16, 2026 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-advances-multikine-xae-immunotherapy-for-hea-7772722644559734.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 16 Jun 2026 08:00:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[U.S. Confirmatory Registration Study expected to begin Summer 2026         Multikine achieved a 73% five-year survival rate versus 45% for standard of care alone in the target patient population and improved quality of life         Saudi partnership includes a 50%/50% net revenue share and suppor...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-advances-multikine-xae-immunotherapy-for-hea-7772722644559734.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews June 14, 2026 07:03:00 pm</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-corporation-announces-pricing-of-offering-8499677152621609.html?utm_source=rss-news-releases</link>
            <pubDate>Sun, 14 Jun 2026 19:03:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[CEL-SCI Corporation (&#x201C;CEL-SCI&#x201D; or the &#x201C;Company&#x201D;) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts offering of 2,500,000 shares of common stock at an offering price of $1.00 per share. Total gross proceed...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-corporation-announces-pricing-of-offering-8499677152621609.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews June 12, 2026 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-and-saudi-amarox-to-conduct-signing-ceremony-5365540805971263.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 12 Jun 2026 08:00:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[Saudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030         Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing &amp; Opening Ceremonies         Strategic Agreement Marks Important Step Toward Commercialization of Multikine   &#x...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-and-saudi-amarox-to-conduct-signing-ceremony-5365540805971263.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews May 18, 2026 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-reports-fiscal-second-quarter-2026-results-4610216277254024.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 18 May 2026 08:00:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026             Signed Key Partnership with Amarox to Advance Multikine Approval and Commercialization in Saudi Arabia             50%/50% revenue sharing agreement for Multikine sales in Saudi Arabi...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-reports-fiscal-second-quarter-2026-results-4610216277254024.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews May 13, 2026 03:00:00 pm</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-announces-closing-of-public-offering-7248359407095063.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 13 May 2026 15:00:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[CEL-SCI Corporation (&#x201C;CEL-SCI&#x201D; or the &#x201C;Company&#x201D;) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts public offering of 6,000,000 shares of its common stock. Each share of common stock was sold at a publi...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-announces-closing-of-public-offering-7248359407095063.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews May 11, 2026 08:11:00 pm</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-corporation-announces-pricing-of-public-offe-5816103000815676.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 11 May 2026 20:11:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[CEL-SCI Corporation (&#x201C;CEL-SCI&#x201D; or the &#x201C;Company&#x201D;) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 6,000,000 shares of its common stock at an offering price of $1.20 per share. Total gr...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-corporation-announces-pricing-of-public-offe-5816103000815676.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews May 11, 2026 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-enters-strategic-agreement-with-amarox-for-t-6225541797368559.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 11 May 2026 08:00:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[50%/50% revenue sharing agreement       for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation           Amarox to act as the local regulatory representative       and lead all communications with the Saudi Food and Drug Authority (SFDA)           Amarox ranked #1 f...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-enters-strategic-agreement-with-amarox-for-t-6225541797368559.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews February 18, 2026 09:00:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-reports-fiscal-first-quarter-2026-results-8425184415942799.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 18 Feb 2026 09:00:00 -0500</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[Set to Commence Patient Enrollment Summer of 2026 in Pivotal U.S. FDA Head and Neck Cancer Registration Study             Entering Saudi Oncology Market, Potentially Through Key Partnerships to Advance Multikine Approval and Commercialization               CEL-SCI Corporation   (NYSE American: CV...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-reports-fiscal-first-quarter-2026-results-8425184415942799.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews December 29, 2025 09:00:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-reports-fiscal-2025-results-5310135672761484.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 29 Dec 2025 09:00:00 -0500</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[Filed for Breakthrough Designation for Multikine in Saudi Arabia             A 212-patient Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients is currently in final stage of preparations - enrollment expected to begin Spring 2026             Pl...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-reports-fiscal-2025-results-5310135672761484.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews October 20, 2025 09:00:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-presentation-at-ld-micro-main-event-availabl-8591688476367414.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 20 Oct 2025 09:00:00 -0400</pubDate>
            <dc:creator><![CDATA[Newsfile]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[Vienna, Virginia--(Newsfile Corp. - October 20, 2025) - CEL-SCI Corporation  (NYSE American: CVM) , a clinical stage cancer immunotherapy company, previously announced that Geert Kersten, Chief Executive Officer, is scheduled to present at the  LD Micro "Main Event"  Investor Conference on Octobe...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-presentation-at-ld-micro-main-event-availabl-8591688476367414.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews October 10, 2025 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-corporation-to-present-at-ld-micro-main-even-4881253108969667.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 10 Oct 2025 08:00:00 -0400</pubDate>
            <dc:creator><![CDATA[Newsfile]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[Vienna, Virginia--(Newsfile Corp. - October 10, 2025) - CEL-SCI Corporation  (NYSE American: CVM) , a clinical stage cancer immunotherapy company, today announced that Geert Kersten, Chief Executive Officer, is scheduled to present at the  LD Micro "Main Event"  Investor Conference on October 21,...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-corporation-to-present-at-ld-micro-main-even-4881253108969667.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews August 29, 2025 12:52:00 pm</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-announces-closing-of-10-million-public-offer-7858877062546785.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 29 Aug 2025 12:52:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[CEL-SCI Corporation (&#x201C;CEL-SCI&#x201D; or the &#x201C;Company&#x201D;) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its offering of 1,111,200 shares of its common stock. Each share of common stock was sold at a public offering price of ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-announces-closing-of-10-million-public-offer-7858877062546785.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews August 27, 2025 10:35:00 pm</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-announces-pricing-of-10-million-public-offer-8813224285444659.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 27 Aug 2025 22:35:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[CEL-SCI Corporation (&#x201C;CEL-SCI&#x201D; or the &#x201C;Company&#x201D;) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 1,111,200 shares of its common stock. Each share of common stock is being sold at a pu...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-announces-pricing-of-10-million-public-offer-8813224285444659.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews August 14, 2025 10:45:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-reports-fiscal-third-quarter-2025-financial--8733410768286959.html?utm_source=rss-news-releases</link>
            <pubDate>Thu, 14 Aug 2025 10:45:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[CEL-SCI to sign partnership agreement in Saudi Arabia&#x2014;Potential for patient access and reimbursement/sale of Multikine in Saudi Arabia within approximately 60 days following filing for Breakthrough Medicine Designation               CEL-SCI Corporation   (NYSE American: CVM)   today report...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-reports-fiscal-third-quarter-2025-financial--8733410768286959.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews August 13, 2025 09:15:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-s-multikine-head-and-neck-cancer-immunothera-5377304342464475.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 13 Aug 2025 09:15:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[Memorandum of Understanding (MOU) signed with a leading Saudi Arabian pharma company which submitted the Breakthrough Medicine Designation to the Saudi Food and Drug Authority (SFDA)             Increasing interest in CEL-SCI from Saudi investment funds as Multikine advances through regulatory an...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-s-multikine-head-and-neck-cancer-immunothera-5377304342464475.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews July 14, 2025 04:05:00 pm</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-announces-closing-of-5-7-million-offering-pr-4695188199213914.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 14 Jul 2025 16:05:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[CEL-SCI Corporation (&#x201C;CEL-SCI&#x201D; or the &#x201C;Company&#x201D;) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering pr...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-announces-closing-of-5-7-million-offering-pr-4695188199213914.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews July 11, 2025 12:16:00 pm</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-announces-pricing-of-5-7-million-offering-pr-6554008423664214.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 11 Jul 2025 12:16:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[CEL-SCI Corporation (&#x201C;CEL-SCI&#x201D; or the &#x201C;Company&#x201D;) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock is being sold at an offering...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-announces-pricing-of-5-7-million-offering-pr-6554008423664214.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews July 11, 2025 09:15:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-to-sign-partnership-agreement-with-leading-s-8644091392879983.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 11 Jul 2025 09:15:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[Strong interest from Saudi investment funds in CEL-SCI, Multikine, and potential joint venture to address the wider Middle East and North Africa market             Patient access and reimbursement/sale in Saudi Arabia within approximately 60 days following filing for Breakthrough Medicine Designa...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-to-sign-partnership-agreement-with-leading-s-8644091392879983.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews June 18, 2025 09:00:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/fda-s-approval-of-keytruda-for-pd-l1-positive-head-a-4751093198723554.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 18 Jun 2025 09:00:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[FDA priority review and approval based on interim results sets a positive precedent, paving the path for future Multikine approval             Multikine reduced the risk of death by 66% compared to standard of care in the target population of patients with low and zero PD-L1, while Keytruda reduc...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/fda-s-approval-of-keytruda-for-pd-l1-positive-head-a-4751093198723554.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews May 21, 2025 04:05:00 pm</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-announces-proposed-public-offering-8793826031325788.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 21 May 2025 16:05:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[CEL-SCI Corporation (&#x201C;CEL-SCI&#x201D; or the &#x201C;Company&#x201D;)   (NYSE American: CVM)   , a clinical stage cancer immunotherapy company,     today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (&#x201C;Pre-Funded Warrants&#x201D;) ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-announces-proposed-public-offering-8793826031325788.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews May 21, 2025 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-s-multikine-investigational-cancer-medicine--6464143376656584.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 21 May 2025 08:00:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[Saudi Arabia&#x2019;s new Breakthrough Medicine Designation, if granted, would make Multikine available for patient access and commercial use             Saudi Food and Drug Authority typically responds to Breakthrough Medicine Designation applications within approximately 60 days             Mul...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-s-multikine-investigational-cancer-medicine--6464143376656584.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews May 19, 2025 02:40:00 pm</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-announces-combination-of-common-stock-4809718907102505.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 19 May 2025 14:40:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[CEL-SCI Corporation   (NYSE American: CVM)   announced today that during its annual Shareholder&#x2019;s Meeting on May 19, 2025, a combination was authorized for its outstanding shares of common stock. On May 19, 2025, the Board of Directors approved a 1 for 30 combination of common stock. CEL-S...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-announces-combination-of-common-stock-4809718907102505.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews May 15, 2025 09:00:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-reports-fiscal-second-quarter-2025-financial-8075743373178619.html?utm_source=rss-news-releases</link>
            <pubDate>Thu, 15 May 2025 09:00:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[Plans to file for approval with Breakthrough Therapy Designation in Saudi Arabia based on completed Phase 3 results               CEL-SCI Corporation   (NYSE American: CVM)   today reported financial results for the three months ended March 31, 2025, as well as key recent clinical and corporate d...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-reports-fiscal-second-quarter-2025-financial-8075743373178619.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews April 23, 2025 08:30:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-to-file-for-regulatory-approval-of-multikine-8393523441630575.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 23 Apr 2025 08:30:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[Concluded a successful meeting with Saudi Food and Drug Authority             CEL-SCI was encouraged to apply for Conditional Approval with Breakthrough Therapy Designation based on data from its concluded Phase 3 study             Evaluating Saudi Arabia-based partnerships to potentially fund lo...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-to-file-for-regulatory-approval-of-multikine-8393523441630575.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews April 08, 2025 09:51:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/new-study-in-the-scientific-journal-cancer-cell-supp-4713114611511202.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 08 Apr 2025 09:51:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[Head and neck cancer patients treated with Multikine who had complete or partial tumor responses before surgery had improvements in overall survival, suggesting pre-surgical tumor response is a strong indicator of efficacy and leads to improved overall survival             A third-party head and ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/new-study-in-the-scientific-journal-cancer-cell-supp-4713114611511202.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews March 24, 2025 09:00:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-reports-new-data-treatment-with-multikine-re-5507361218443418.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 24 Mar 2025 09:00:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[Data published in peer-reviewed scientific journal Pathology and Oncology Research         Quality of life improvements included reduction in or cessation of pain in the head and neck area, improvement or complete restoration in ability to eat, drink, and swallow, ability for selfcare including w...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-reports-new-data-treatment-with-multikine-re-5507361218443418.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews March 18, 2025 04:05:00 pm</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-announces-closing-of-2-5-million-offering-7867956697076842.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 18 Mar 2025 16:05:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[CEL-SCI Corporation (&#x201C;CEL-SCI&#x201D; or the &#x201C;Company&#x201D;) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced best-efforts offering of 16,000,000 shares of its common stock (or pre-funded warrants (&#x201C;Pre-Fu...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-announces-closing-of-2-5-million-offering-7867956697076842.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews March 17, 2025 03:24:00 pm</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-announces-pricing-of-2-5-million-offering-8673016545483736.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 17 Mar 2025 15:24:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[CEL-SCI Corporation (&#x201C;CEL-SCI&#x201D; or the &#x201C;Company&#x201D;) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of a best-efforts offering of 16,000,000 shares of its common stock (or pre-funded warrants (&#x201C;Pre-Funded Warrants&#x201D;) ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-announces-pricing-of-2-5-million-offering-8673016545483736.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews March 17, 2025 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-s-head-and-neck-cancer-registration-study-pr-5914906477776231.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 17 Mar 2025 08:00:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[Growing body of data on PD-L1 as a cancer biomarker spurs interest             Working towards partnership for non-dilutive funding of the final confirmatory head and neck cancer Registration Study                 CEL-SCI Corporation     (NYSE American: CVM)   today announced it received comments...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-s-head-and-neck-cancer-registration-study-pr-5914906477776231.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews March 14, 2025 08:30:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/journal-of-the-american-medical-association-jama-stu-4945889827575948.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 14 Mar 2025 08:30:00 -0400</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[The DEPEND study demonstrates that checkpoint inhibitor     nivolumab (Opdivo&#xAE;)     works best with high levels of PD-L1 biomarker, but does not work well with low levels of PD-L1             Multikine* is uniquely positioned in the field as the only oncology drug used as a neoadjuvant that ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/journal-of-the-american-medical-association-jama-stu-4945889827575948.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews February 20, 2025 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-to-initiate-multikine-confirmatory-phase-3-c-8216790026111185.html?utm_source=rss-news-releases</link>
            <pubDate>Thu, 20 Feb 2025 08:00:00 -0500</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[Confirmatory Phase 3 Trial Designed to Support Commercialization of Multikine for Head and Neck Cancer Treatment         Full enrollment expected by Q2 2026 with plans to seek early approval at that time based on early tumor responses&#x2014;Potential to set a new standard of care               C...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-to-initiate-multikine-confirmatory-phase-3-c-8216790026111185.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews February 18, 2025 08:30:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-reports-fiscal-q1-2025-financial-results-mul-5206850327883564.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 18 Feb 2025 08:30:00 -0500</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[CEL-SCI Corporation   (NYSE American: CVM)   today reported financial results for three months ended December 31, 2024, as well as key recent clinical and corporate developments.     &#x201C;CEL-SCI is very uniquely positioned at this moment as an immuno-oncology company with a vast amount of dat...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-reports-fiscal-q1-2025-financial-results-mul-5206850327883564.html?s=cvm?v=<?php echo 3426;?></guid>
            </item><item>
            <title>$CVM CelSci Corporation #MWN #BreakingNews January 14, 2025 09:00:00 am</title>
            <link>https://marketwirenews.com/stock/cvm/news/cel-sci-reports-fiscal-2024-results-set-to-commence--5524185825383024.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 14 Jan 2025 09:00:00 -0500</pubDate>
            <dc:creator><![CDATA[Business Wire]]></dc:creator>
            <category><![CDATA[CVM]]></category>
            <category><![CDATA[Cel-Sci Corporation]]></category>
            <description><![CDATA[A 212-patient Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients is currently in final stage of start-up preparations - full enrollment expected by Q2 2026             Plans to seek early approval based on pre-surgical response rates          ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/cvm/news/cel-sci-reports-fiscal-2024-results-set-to-commence--5524185825383024.html?s=cvm?v=<?php echo 3426;?></guid>
            </item>
	</channel>
</rss>